MERZ-AESTHETICS
31.3.2022 09:02:11 CEST | Business Wire | Press release
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 20th Aesthetic & Anti-Aging Medicine World Congress (AMWC), with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diverse society. AMWC 2022, held from Thursday, 31 March to Saturday, 02 April 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Monaco and/or virtually. Merz Aesthetics is an elite sponsor of the global industry congress.
“As part of our continued commitment to the aesthetic medicine industry, we are looking forward to reunite with partners and experts, share insights and foster scientific exchange in the aesthetics field at this year’s AMWC congress,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We are focused to advance science in aesthetics, fuel confidence and empower unique attitudes.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs – by fueling confidence and empowering unique attitudes.
Merz Aesthetics is organizing an expert program led by esteemed medical aesthetic experts and presenting new data throughout the course of the meeting.
Expert Keynote Sessions
Merz Aesthetics is organizing expert-led keynote sessions to be held on Thursday, 31 March – Friday, 01 April (via registration only).
- “Skin Glow and Skin Quality – optimizing your skin boosting treatment” – Dr. Sonja Sattler, Thursday, 31 March, 10:00-12:00h CEST.
- “Collagen Expert Class – insights into collagen stimulation, skin quality and patient safety” – Dr. Jani van Loghem, Thursday, 31 March, 13:00-15:00h CEST.
- “Optimizing the Patient Journey in the Digital Age” – Adam Haroun, Thursday, 31 March, 15:30-17:00h CEST.
- “Aesthetic Toxin Expert Talk – purity and precision for long-term patient satisfaction” – Dr. Carla Pecora, Friday 01 April, 10:00-12:00h CEST.
- “Skin Lifting – the expert approach to customized treatments” – Dr. Tatjana Pavicic, Friday 01 April, 13:00-15:00h CEST.
- “All About Lips – expert techniques to address the unique needs of patients” – Dr. Kate Goldie, Friday 01 April, 15:30 – 17:30h CEST
Oral Presentations
Dr. Carla Pecora: ‘Clinical experience with intradermal microdroplet injection of diluted Incobotulinum toxin A for facial flushing and pore size improvement’ (Neuromodulators); Saturday, 02 April, 9:00h CEST, Nijinski
Dr. Carla Pecora: ‘A combination approach using IncobotulinumtoxinA and CPM-HA injections for the periorbital complex improvement.’ (Periorbital Zone and “Foxy Eyes” Trend – Lifting & Rejuvenating); Saturday, 02 April, 11:15h CEST, Salle des Princes & AMWC Stream 1
E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A LONGitudinal evaluation and Real-world evidence of Uniquely purified incobotulinumtoxinA in treatment naïve participants. Andy Curry, Merz Aesthetics - USA, Terrence Keaney, MD – USA, Niamh Corduff, MD – Australia, Simon Ravichandran, MD – UK, Ada Trindade, MD – Brasil.
- Chemobioresurfacing: Does intradermal injection of botulinumtoxinA plus hyaluronic acid improve skin quality? Diane Duncan, MD – USA.
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- The local tissue lifting capacity of dermal filler is greater with increasing hyaluronic acid concentration using an ex vivo human skin model. Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Thomas Hengl – all Merz Aesthetics, Germany.
- Distance between calcium hydroxylapatite microspheres is essential for fibroblast invasion and resulting neocollagenesis. Bartosch Nowag, Nils Warfving, Thomas Hengl – all Merz Aesthetics, Germany.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Yana Yutskovskaya, MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com .
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 16:33:00 CEST | Press release
New analysis shows destinations that assume risk will recover up to 1.5 times faster with global rehabilitation times dropping from 24 months to as little as 10 TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and mai
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 15:00:00 CEST | Press release
New admin-defined spend rules let businesses control how, where, and when every card is used, stopping the wrong spend before it happens instead of cleaning it up after. Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or le
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 14:30:00 CEST | Press release
New Travel Industry report reveals sophisticated fraud rings are exploiting trusted customer behaviors across flights, hotels, and travel platforms Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity i
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 13:54:00 CEST | Press release
Revenue rose 9% to $120 billion while net profit more than doubled to $17 billionCumulative domestic investments reached more than $199 billion since 2021PIF has contributed more than $342 billion to Saudi Arabia’s real non-oil GDP between 2021 and 2025Assets under management exceed $900 billion, up from around $530 in 2021 and $150 billion in 2015 PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom